![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Equasens | LSE:0R9T | London | Ordinary Share | FR0012882389 | EQUASENS |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 62.20 | 9 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Computer Programming Service | 222.57M | 47.05M | 3.1005 | 17.84 | 839.12M |
Villers-lès-Nancy, 2 January 2024 - 6:00 p.m. (CET)
PRESS RELEASE
Acquisition of a majority stake in DIGIPHARMACIE, An expert in digital and invoice management solutions for pharmacies
Equasens Group, a leading healthcare software publisher (Euronext Paris™ - Compartment A - ISIN: FR 0012882389 - Ticker EQS) today announces its acquisition of a 70% majority stake in the start-up DIGIPHARMACIE.
An innovative and profitable young company
Based in the Paris region and created in 2019, DIGIPHARMACIE is a pure player in digital invoicing solutions for pharmacies. As a provider of SaaS (Software as a Service) solutions for pharmacies, the DNA of this French start-up, led by Yonathan BLAJMAN, David CHALOM and Jonathan FITOUSSI, includes a significant technological component by enabling pharmacies to automatically collect, centralise and store supplier invoices and using artificial intelligence to digitise and structure data flows to the applications used by their external accountants. DIGIPHARMACIE's ready-to-deploy offering also addresses the needs of the pharmaceutical industry. As such, it already complies with the obligation requiring all invoices to be sent and received electronically by 1 September 2026.
With an installed base of already nearly 70% of French pharmacies (13,000 pharmacy customers), nearly 300 accounting firms, including major national groups, and an agreement with nearly 80% of pharmacy groups, DIGIPHARMACIE processes more than 1 million invoices each month on its platform.
Reflecting its achievements, in 2023 DIGIPHARMACIE was a recipient of the Prix de l'Innovation PharmagoraPlus (PharmagoraPlus Innovation Award).
"This acquisition of a majority stake in Digipharmacie provides yet another confirmation of the Equasens Group's commitment to supporting innovative start-ups,” commented Denis SUPPLISSON, Chief Executive Officer of Equasens. "DIGIPHARMACIE has been profitable since its creation in 2019 and has very quickly become the leader in its market. As a result of this acquisition, we are now able to offer pharmacists and their chartered accountants a complete and disruptive solution to meet their needs in the area of electronic invoicing."
"We are delighted to become a member of the Equasens Group, which will provide us with invaluable expertise and support our continued growth and development” stated Yonathan BLAJMAN, pharmacist and co-founder of DIGIPHARMACIE, adding that "As a result of this alliance, we are now able to offer our customers a more comprehensive and innovative range of services, and address the growing need for more of effective and efficient digital solutions in the healthcare ecosystem."
Electronic invoicing: an indispensable new development for healthcare professionals in France.
Equasens' acquisition of a majority stake in DIGIPHARMACIE represents an important turning point in the digital transformation of the healthcare sector. On this basis, the two companies are now able to offer a comprehensive solution that addresses the new requirement for all invoices to be received in electronic form by 1 September 2026.
Through this collaboration, the two companies will be able to extend the range of functions available to pharmacists to further simplify and secure their administrative workload. It will also make it possible to extend this approach to other healthcare professionals.
About Group Equasens
Founded more than 35 years ago, Equasens Group, which now has more than 1400 employees in Europe, is the leading publisher of software solutions for the healthcare industry in terms of the diversity of its business applications and market share.
Equasens Group’s specialised business applications facilitate the day-to-day work of healthcare professionals and their teams, working in private practice, collaborative medical structures or healthcare establishments. The Group also provides comprehensive support to healthcare professionals in the transformation of their profession by developing electronic equipment, digital solutions and healthcare robotics, as well as financing and training adapted to their specific needs.
And reflecting the spirit of its tagline "more technology for more humanity", the Group is a leading provider of interoperability solutions that improve coordination between healthcare professionals, their communications and data exchange resulting in better patient care and a more efficient healthcare system.
Listed on Euronext Paris™ - Compartment A
Indexes: MSCI GLOBAL SMALL CAP - GAÏA Index 2020 - CAC® SMALL and CAC® All-TradableIncluded in the Euronext Tech Leaders segment and the European Rising Tech label
Eligible for the Deferred Settlement Service (“Service à Réglement Différé” - SRD) and equity savings accounts invested in small and mid caps (PEA-PME).ISIN: FR 0012882389 – Ticker Code: EQS
Get all the news about the Equasens Group www.equasens.com and on LinkedIn
CONTACTS
Analyst and Investor Relations: Chief Administrative and Financial Officer: Frédérique SCHMIDTTel.: +33 (0)3 83 15 90 67 - frederique.schmidt@equasens.com
Financial Press: FIN’EXTENSO - Isabelle APRILE
Tel.: +33 (0)6 17 38 61 78 – i.aprile@finextenso.fr
Attachment
1 Year Equasens Chart |
1 Month Equasens Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions